Further, ongoing studies are evaluating the combinations of PD-1, PD-L1, and/or CTLA-4 monoclonal antibodies with other chemotherapeutic molecules, which will re-activate the immune system against CRC tumors (Table 1). This evidence concerns the gene CTLA4 and colorectal carcinoma.